Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHELLE ELISABETH EISENBERG

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1740215375
CMS profile
214525
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$6,892.83

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $3,533.00 3
Food and Beverage $2,872.51 134
Travel and Lodging $459.54 1
Education $27.78 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHELLE ELISABETH EISENBERG

NPI 1740215375 · CMS profile ID 214525

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740215375?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHELLE ELISABETH EISENBERG, NPI 1740215375, CMS profile ID 214525. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740215375?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHELLE ELISABETH EISENBERG, NPI 1740215375, CMS profile ID 214525. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740215375?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHELLE ELISABETH EISENBERG, NPI 1740215375, CMS profile ID 214525, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740215375?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $6,892.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $5.3209/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629509 CMS
Janssen Biotech, Inc. $13.3308/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788626031 CMS
E.R. Squibb & Sons, L.L.C. $14.7808/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783471459 CMS
AbbVie Inc. $23.8608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399189 CMS
Alexion Pharmaceuticals, Inc. $20.9808/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783132401 CMS
AbbVie Inc. $5.0608/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399187 CMS
AstraZeneca Pharmaceuticals LP $15.1808/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829877839 CMS
Novartis Pharmaceuticals Corporation $17.2508/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812668733 CMS
Janssen Biotech, Inc. $31.6708/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788626025 CMS
AbbVie Inc. $18.4808/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399185 CMS
Amgen Inc. $8.5108/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629469 CMS
Janssen Biotech, Inc. $6.7008/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788626039 CMS
Amgen Inc. $26.3307/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629505 CMS
AstraZeneca Pharmaceuticals LP $15.7307/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830107947 CMS
E.R. Squibb & Sons, L.L.C. $7.9207/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783471455 CMS
AbbVie Inc. $6.1707/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399183 CMS
E.R. Squibb & Sons, L.L.C. $16.6707/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783471451 CMS
AbbVie Inc. $18.2007/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399181 CMS
Amgen Inc. $5.4606/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629441 CMS
Amgen Inc. $13.8906/28/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826536415 CMS
GlaxoSmithKline, LLC. $23.8906/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802879913 CMS
AstraZeneca Pharmaceuticals LP $16.6506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829399567 CMS
Amgen Inc. $24.1406/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629465 CMS
AbbVie Inc. $24.6306/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399179 CMS
AbbVie Inc. $124.9806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399177 CMS
E.R. Squibb & Sons, L.L.C. $18.1506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783471441 CMS
Novartis Pharmaceuticals Corporation $23.4406/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812668731 CMS
AbbVie Inc. $2.3306/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399175 CMS
GlaxoSmithKline, LLC. $18.2406/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802054917 CMS
AbbVie Inc. $28.7005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399173 CMS
Janssen Biotech, Inc. $17.2805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788626041 CMS
Alexion Pharmaceuticals, Inc. $19.1105/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783132389 CMS
Amgen Inc. $29.6905/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629461 CMS
AstraZeneca Pharmaceuticals LP $12.5405/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829672987 CMS
AbbVie Inc. $24.9405/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399171 CMS
AbbVie Inc. $5.9705/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399169 CMS
GlaxoSmithKline, LLC. $16.0205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801769749 CMS
Amgen Inc. $5.8005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629437 CMS
Horizon Therapeutics plc $9.4705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797117547 CMS
Amgen Inc. $20.6205/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629497 CMS
Novartis Pharmaceuticals Corporation $14.8705/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812668729 CMS
Amgen Inc. $6.7905/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629501 CMS
Horizon Therapeutics plc $8.4205/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797117541 CMS
Radius Health, Inc. $15.7605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830708209 CMS
E.R. Squibb & Sons, L.L.C. $18.3105/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783471437 CMS
Horizon Therapeutics plc $10.8405/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797117537 CMS
Janssen Biotech, Inc. $18.9004/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788626043 CMS
Ultragenyx Pharmaceutical Inc. $31.7804/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848972863 CMS
Amgen Inc. $20.9804/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825629457 CMS
AbbVie Inc. $16.3904/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794399167 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,230.68 195
PY2020 $2,304.43 133
PY2021 $6,892.83 140
PY2022 $25,281.19 183
PY2023 $3,844.28 185
PY2024 $5,978.52 163
PY2025 $5,489.62 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,021,219.52 32
PY2024 Principal investigator $407,356.92 14
PY2023 Principal investigator $62,556.89 6
PY2022 Principal investigator $42,669.75 88
PY2021 Principal investigator $95,433.10 51
PY2020 Principal investigator $99,198.50 31
PY2019 Principal investigator $13,494.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $15,754.50 12/22/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226114026
Principal investigator 1 Novartis Pharmaceuticals Corporation $74,089.60 12/02/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190310126
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $19,350.00 11/19/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225336265
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190310122
Principal investigator 1 SANOFI US SERVICES INC. $9,544.00 10/27/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113996
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,625.54 10/01/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190310154
Principal investigator 1 Amgen Inc. $34,539.65 09/12/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646880
Principal investigator 1 SANOFI US SERVICES INC. $4,080.00 09/03/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113978
Principal investigator 1 SANOFI US SERVICES INC. $8,398.00 08/18/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113955
Principal investigator 1 SANOFI US SERVICES INC. $4,228.00 08/18/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113960
Principal investigator 1 SANOFI US SERVICES INC. $4,376.00 08/18/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113965
Principal investigator 1 Amgen Inc. $31,158.38 08/15/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246646876
Principal investigator 1 Amgen Inc. $156.22 07/28/2025 Non-covered Recipient Entity
PROLATO CLINICAL RES.CENTER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646836
Principal investigator 1 Amgen Inc. $106.77 07/28/2025 Non-covered Recipient Entity
PROLATO CLINICAL RSCH.CENTER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646856
Principal investigator 1 SANOFI US SERVICES INC. $7,607.50 07/02/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113912
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,000.00 05/22/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190309980
Principal investigator 1 SANOFI US SERVICES INC. $41,630.00 05/19/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113888
Principal investigator 1 SANOFI US SERVICES INC. $30,403.50 05/19/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113901
Principal investigator 1 SANOFI US SERVICES INC. $8,537.50 05/19/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226113907
Principal investigator 1 UCB SA $41,073.40 05/07/2025 Non-covered Recipient Entity
Prolato Clinical Research Center
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659498
Principal investigator 1 Amgen Inc. $20,724.73 05/01/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome No dispute reported 06/30/2026 1246646872
Principal investigator 1 Amgen Inc. $283,127.81 04/23/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases No dispute reported 06/30/2026 1246646844
Principal investigator 1 Amgen Inc. $3,085.20 04/21/2025 Non-covered Recipient Entity
PROLATO CLINICAL RSRCH. CENTER
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246646860
Principal investigator 1 Novartis Pharmaceuticals Corporation $148,736.39 04/08/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190310128
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,191.00 03/25/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190311097
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,032.50 01/28/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190311095
Principal investigator 1 UCB SA $1.07 01/17/2025 Non-covered Recipient Entity
Prolato Clinical Research Center
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657451
Principal investigator 1 Amgen Inc. $19,023.32 01/15/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome No dispute reported 06/30/2026 1246646840
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,721.44 01/06/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190310124
Principal investigator 1 Amgen Inc. $13,103.75 01/03/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
P2 HZN-1116-201 Sjogren's Syndrome (SS) No dispute reported 06/30/2026 1246646852
Principal investigator 1 AstraZeneca Pharmaceuticals LP $82,735.24 01/03/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185554184
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,061.39 01/01/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190310156